Mr. Francois Roberge reports

LSL PHARMA GROUP ANNOUNCES VOTING RESULTS OF ITS ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

LSL Pharma Group Inc. has released the results of its annual and special meeting of shareholders, held today in Montreal, Que.

The shareholders approved, by a majority of votes, resolutions to elect each of the following directors: Diane Beaudry, Frank J. DellaFera, Stuart W. Fowler, Pierre Lafreniere, Mario Paradis, Francois Roberge (chairman) and Joseph Soccodato.

In addition, the shareholders of the company, by a majority of votes, proceeded with the appointment of KPMG LLP as the auditor of the corporation, authorized the directors to fix its remuneration and approved the 10-per-cent rolling stock option plan of the corporation.

Mr. Roberge commented: "It is my pleasure to welcome Mr. Soccodato and Mr. Fowler on our board of directors. Their extensive board experience and valuable industry-specific knowledge make them key contributors to assist LSL Pharma Group in implementing its growth initiatives."

New directors

Mr. Fowler has over 25 years of experience in the health sciences space in North America. He began his career with Allergan in 1993 in sales within its eye care division. Over the next 23 years, he held numerous roles with increased responsibility in sales, marketing and management. In his previous executive roles, Mr. Fowler led two of Canada's largest ophthalmic pharmaceutical and medical device organizations. He is the past president and general manager of Allergan Canada (AbbVie) from 2010 until his departure in 2015. He was also president and general manager for Alcon Canada from 2016 to 2020. Mr. Fowler is the co-founder and president of the Aesthetic Medicine Network Inc. (AMNI). AMNI is Canada's largest group of independently owned and operated aesthetically oriented physicians, leading initiatives in group purchasing, medical education and market development. Mr. Fowler has also served as director of Aequus Pharmaceuticals Inc. from February, 2020, to March, 2023, and Valeo Pharma Inc. from April, 2023, to February, 2024.

Mr. Fowler received a bachelor of arts with specialization in international relations, majoring in economics and political science, from the University of Alberta in 1989. He has also attended numerous graduate business programs, receiving certification in executive leadership from the Marshall School of Business at the University of Southern California.

Mr. Soccodato earned a BS in accounting, cum laude, from Long Island University. He is a certified public accountant and has working proficiency in Italian. He has 30 years of experience in managing and improving international companies, critical departments and worldwide operating divisions. He is currently the chief financial officer of Jacent, the industry leader in strategic impulse merchandising solutions and premier clip strip partner to some of the largest retailers in the United States and Canada. Mr. Soccodato also worked for some of the world's largest accounting firms, as well as serving as the CFO for one of the fastest-growing, specialty grocery chains. He also was the global chief financial/operating/restructuring officer for an international manufacturer, distributor and retailer of consumer products with annual revenue exceeding $400-million.

Mr. Soccodato brings extensive experience leading public, privately held and private-equity-backed enterprises in areas such as accounting, treasury, budgeting, M&A (merger and acquisition), operations and risk management. He has successfully managed all aspects of business transformations, large and small acquisitions, as well as potential exit strategies, such as a sale to a strategic competitor, private equity firm or a public offering.

About LSL Pharma Group Inc.

LSL Pharma Group is an integrated Canadian pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceuticals, as well as natural health products in solid and liquid dosage forms.